Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company says could lead to faster and more complete disease control.

The company believes its lead drug, which is currently in mid-stage testing, could address limitations of other therapies for ...

The U.S. Food and Drug Administration has approved Novartis' oral treatment for patients with type of chronic inflammatory ...

Thermo Fisher Scientific announced an R&D partnership with AstraZeneca BioVentureHub. Crinetics received FDA approval of Palsonify (paltusotine) to treat acromegaly in adults. The agency approved ...

The FDA approved remibrutinib, the first oral treatment for adults with persistent chronic spontaneous urticaria despite H1 ...

The first head-to-head randomized clinical trial to compare biologics in severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma showed an advantage to dupilumab (Dupixent) over ...

On Sept. 22, President Donald Trump pushed an unproven link between Tylenol and an increase in autism in children, and he issued an urgent warning to expectant mothers not to take the medication. What ...

Omalizumab is indicated for the treatment of persistent asthma, chronic rhinosinusitis with nasal polyps, food allergies and ...

Following multiple years of rumors, this was the year that Apple’s Pro iPhones finally got a vapor chamber to help dissipate heat. If you’ve never really looked into or understood how this component ...

One post is all it takes to become a target of doxxing. Learn how your online activity can be used against you and the steps you can take right now to safeguard your privacy.

GameSpot may get a commission from retail offers. EA and Battlefield Studios have clarified how cross-play works for Battlefield 6 as it relates to consoles, following a period of confusion based on ...

On September 26, AMRX submitted a Biologics License Application (BLA) for a biosimilar to XOLAIR® (omalizumab), targeting a ...